Merck (MRK) Q1 2026: Oncology Portfolio Hits $8B, Pipeline and AI Drive Next Decade’s Growth
Merck’s first quarter revealed a business in active transformation, with a diversified pipeline and major investments in AI and targeted acquisitions signaling a pivot from legacy dependence on Keytruda. Robust oncology and animal health growth offset vaccine headwinds, while the company’s evolving portfolio and new operating structure position it for a $70B opportunity by the mid-2030s. Investors should focus on the timing of upcoming data readouts, integration of new assets, and the execution of Merck’s AI-driven strategy as critical levers for long-term value creation.
Summary
- Portfolio Diversification Accelerates: Oncology and animal health outperformed as Merck advances over 20 new launches with blockbuster potential.
- AI and Business Unit Overhaul: New commercial structure and AI partnerships aim to improve execution and pipeline productivity.
- Upcoming Data Readouts Critical: Multiple late-stage milestones and regulatory decisions in the next 18 months will shape long-term growth trajectory.
Performance Analysis
Merck delivered 5% revenue growth in the first quarter, with oncology and animal health driving the topline. The Keytruda franchise, immuno-oncology leader, posted $8 billion in sales, up 8% ex-FX, sustained by strong demand across metastatic and earlier-stage cancers, especially in women’s health and urothelial cancer. Animal health sales rose 6%, with livestock and companion animal segments both contributing despite some softness in vet visits. New launches such as Keytruda-Qlex and Numelvi, a second-generation JAK inhibitor for dogs, began to make tangible contributions.
However, Gardasil, HPV vaccine, saw a 22% sales decline due to weaker demand in Asia and US timing effects, partially offset by price. The respiratory portfolio showed mixed results: Winrever, PAH therapy, maintained momentum, but Otover, COPD treatment, was impacted by reimbursement changes. Operating expenses were elevated by a $9 billion one-time charge for the Sedera acquisition, resulting in a reported pre-tax loss and negative EPS for the quarter. Excluding this, underlying expense growth was modest, reflecting disciplined investment in launches and pipeline. The company raised its full-year revenue and EPS guidance midpoints, reflecting confidence in its diversified growth drivers.
- Oncology Outperformance: Keytruda and WelliReg drove robust growth, with new indications and launches fueling momentum.
- Vaccine Volatility: Gardasil and influenza franchises faced timing and regional headwinds, but pipeline data may reset the narrative.
- Expense Management: Underlying operating expenses rose only 2% ex-acquisition, despite stepped-up launch investments.
Cash flow remains strong and capital allocation disciplined, with $3 billion in share repurchases on track and a continued commitment to the dividend. The company’s financial health supports ongoing M&A and pipeline investment.
Executive Commentary
"Advancing and delivering breakthrough science to address unmet medical needs remains the foundation of our strategy to create sustainable value for patients and shareholders. We continue to make tangible progress, in accelerating and augmenting our pipeline, and with the recent new product launches, the transformation of our portfolio to a far more diversified set of commercial drivers is now well underway."
Rob Davis, Chairman and Chief Executive Officer
"Our commercial and operational execution continues to enable us to generate strong results in the short term while we advance our broad and deep pipeline and invest in innovation to deliver long-term value for patients, customers, and shareholders. We have narrowed the range and raised the midpoint of both our full-year revenue and EPS guidance."
Caroline Litchfield, Chief Financial Officer
Strategic Positioning
1. Oncology Leadership and Expansion
Merck’s oncology engine remains central, with Keytruda’s 44 FDA indications and two tumor-agnostic approvals. The company is leveraging combination regimens and new launches (Keytruda-Qlex, WelliReg) to extend its reach into earlier-stage and additional cancer types. Priority reviews for Keytruda and WelliReg in new settings, plus the IDXD antibody-drug conjugate (ADC) collaboration with Daiichi Sankyo, reinforce oncology’s role as the growth anchor.
2. Pipeline Transformation and Business Development
Over 20 new product launches are underway, most with blockbuster potential. The Terns Pharmaceuticals acquisition (Turn 701, CML therapy) exemplifies Merck’s disciplined approach to external innovation, targeting high unmet need and multibillion-dollar opportunities. The pipeline is diversified across oncology, cardiometabolic, immunology, infectious disease, and ophthalmology, reducing legacy risk.
3. AI and Data Partnerships
Merck is investing aggressively in AI, with a multi-year Google Cloud partnership to scale advanced data and agentic capabilities. Expanded collaborations with Tempus AI and Mayo Clinic are aimed at accelerating precision oncology and leveraging clinical-genomic data. These moves are designed to improve R&D productivity, shorten time-to-market, and enhance commercial execution.
4. Commercial Operating Model Overhaul
The company’s new business unit structure, organized by product and therapeutic area, is intended to sharpen accountability and agility as it manages a more complex, diversified portfolio. This structural change is expected to accelerate launches and maximize the impact of upcoming pipeline milestones.
5. Capital Allocation and Shareholder Returns
Merck continues to prioritize reinvestment in launches and pipeline, while maintaining a strong dividend and opportunistic share repurchases. Management signaled ongoing appetite for M&A, with a focus on science-led, value-accretive deals in the $1–$15 billion range, particularly in oncology, immunology, and cardiometabolic.
Key Considerations
This quarter marks a strategic inflection for Merck, as it shifts from a Keytruda-centric model to a multi-engine growth platform. Investors should weigh the following:
Key Considerations:
- Pipeline Readouts as Catalysts: More than a dozen phase three data releases and regulatory decisions are expected in the next 18 months, with oncology, HIV, and cardiometabolic at the forefront.
- AI Implementation Pace: The effectiveness of the Google Cloud and Tempus AI partnerships will be measured by pipeline advancement and commercial agility over coming quarters.
- Integration of New Assets: Success in realizing Turn 701’s potential and smoothly integrating recent acquisitions will be a litmus test for Merck’s business development discipline.
- Vaccine and Respiratory Franchise Recovery: The trajectory of Gardasil and Otover sales, amid reimbursement and inventory headwinds, will impact near-term growth and sentiment.
- Expense Discipline Amid Expansion: Underlying cost management must continue as launch and R&D investments scale up.
Risks
Merck faces several execution and market risks: Keytruda’s growth is increasingly dependent on new indications and combinations, while biosimilar and competitive pressures loom longer-term. Vaccine sales volatility, especially in Asia, and the challenge of scaling AI and new commercial models could create operational friction. Integration risk from acquisitions and the need to deliver on pipeline milestones also remain material uncertainties. Regulatory delays or negative data readouts in pivotal studies could alter the growth outlook.
Forward Outlook
For Q2 2026, Merck guided to:
- Minimal Influenza sales due to seasonality and high RSV antibody inventory
- SG&A ramp as new launches and pipeline investments accelerate
For full-year 2026, management raised the midpoint of revenue and EPS guidance:
- Revenue: $65.8–$67 billion (1–3% growth, includes FX tailwind)
- EPS: $5.04–$5.16 (excluding impact of the pending Terns acquisition)
Management highlighted:
- Upcoming data from phase three oncology, HIV, and cardiometabolic trials as major catalysts
- Ongoing investment in launches and pipeline, with disciplined capital allocation and continued M&A appetite
Takeaways
Merck is executing a multi-year pivot from a single-product dependency to a diversified, innovation-led growth model, with oncology still central but a deep pipeline and AI-driven capabilities providing new engines. Upcoming clinical and regulatory milestones will be decisive for valuation and sentiment.
- Oncology and Animal Health Anchor Growth: Keytruda and WelliReg momentum, coupled with animal health launches, offset vaccine softness and support guidance raise.
- Pipeline and AI Are the Next Growth Engines: Over 20 launches, new AI partnerships, and a revamped commercial structure set the stage for a $70B opportunity by mid-2030s.
- Watch for Integration and Data Risk: Success hinges on smooth integration of new assets and positive late-stage readouts, especially in oncology and cardiometabolic.
Conclusion
Merck’s Q1 2026 results underscore a company in strategic transition, with diversified growth drivers, pipeline depth, and operational evolution positioning it for long-term outperformance. The next 18 months of data and execution will determine whether Merck’s transformation delivers on its multibillion-dollar promise.
Industry Read-Through
Merck’s shift toward a diversified, AI-enabled portfolio is emblematic of the broader pharmaceutical industry’s move beyond single-product dependency and toward platform-based innovation. The emphasis on AI partnerships, business unit agility, and disciplined external innovation will likely become table stakes for large-cap pharma. Oncology remains the competitive battleground, but the renewed focus on cardiometabolic, immunology, and rare diseases suggests that pipeline diversity and data-driven execution will define winners. Investors should monitor how peers respond to Merck’s aggressive pipeline build, AI adoption, and capital allocation discipline, as these themes will shape sector leadership in the coming decade.